Completed OBSERVATIONAL NCT04867798

Transgender Men and HIV in Uganda: PrEP Uptake and Persistence

Sponsor: Makerere University

Conditions HIV PrEP Sexually Transmitted Infections Transgender Men

Interventions Lamivudine-Tenofovir 300 Mg-300 Mg Oral Tablet

Updated 5 times since 2021 Last updated: Oct 10, 2023 Started: Sep 16, 2021 Primary completion: Apr 30, 2023 Completion: Apr 30, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on HIV and PrEP, this trial is completed. The trial is conducted by Makerere University and has accumulated 5 data snapshots since 2021. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Nov 2023 — Jul 2024 [monthly]

Completed

Status: Recruiting → Completed
Jan 2022 — Nov 2023 [monthly]

Recruiting

Status: Not Yet Recruiting → Recruiting
May 2021 — Jan 2022 [monthly]

Not Yet Recruiting

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Makerere University
Massachusetts General Hospital

Data source: Makerere University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Kampala, Uganda